We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402
News

BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402

BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402
News

BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The first two patient cohorts included in total 200 individuals and the recruitment for the second cohort was concluded in August. The decision to start recruitment of the third patient cohort follows an unanimous recommendation from the external board monitoring the efficacy and safety of the study.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous injection post knee replacement surgery and the trial will enrol 300 patients. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402. All the patients in the study will be monitored for a period of three months after surgery. TB-402 is developed in collaboration with ThromboGenics NV.

Advertisement